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LetterDiffering Standards for the NIH Stem Cell Registry
and FDA Approval Render Most Federally Funded
hESC Lines Unsuitable for Clinical UseThe NIH Guidelines on Human Stem Cell
Research (‘‘the NIH Guidelines’’), finalized
in 2009, states that the NIH will consider
funding research only on human embry-
onic stem cell lines derived from human
embryos ‘‘created using in vitro fertiliza-
tion for reproductive purposes and. no
longer needed for this purpose.’’ Investi-
gators who have derived a new hESC
line must provide to the NIH a copy of
the IVF patient consent for reproductive
treatment, as well as the research con-
sent form signed by the legal parents of
the embryo. Once the NIH is satisfied
that the parents created the embryo for
reproductive purposes and gave volun-
tary written informed consent for its use
for research, the NIH lists the new line
on the NIH Stem Cell Registry of fund-
ing-eligible lines. TheNIHwill not consider
funding research on hESC lines not on
the Registry. Because investigators at
universities and nonprofit research insti-
tutes rely primarily on the NIH for funding
for basic research, translational research,
or both, these investigators primarily
study the hESC lines on the NIH registry.
Likewise, these nonindustry investigators
who are deriving new lines utilize embryos
from consented patients of fertility clinics
so that any new line may be NIH eligible.
The U.S. Food and Drug Administration
regulates the development and marketing
of therapeutic products for human use,
including biologically generated products
such as human tissue and, notably, hu-
man-embryonic-stem-cell-derived prod-
ucts. The FDA’s Tissue Donor Guidance
(2007)describes theeligibility requirements
for tissue donors, whether the tissue
is to be minimally manipulated before
use (e.g., blood) or significantly altered or
manipulated (e.g., genetically modified
cells). Beforedonation, thewould-be tissue
donor must be tested and demonstrated
to be negative/nonreactive for the follow-
ing infectious agents/diseases: HIV types
1 and 2; hepatitis B virus, hepatitis C virus;
human transmissible spongiform ence-
phalophathy (TSE), including Creutzfeldt-
Jakob Disease (CJD) (prion diseases);Treponema pallidum (syphilis); Human
T-lymphotropic virus (HTLV), types I and
II; Chlamydia trachomatis; and Neisseria
gonorrhea. The screen for prion diseases
includes an extensive interview with the
would-be donor because, as the FDA’s
Guidance asserts, ‘‘There are currently
no FDA-licensed, approved, or cleared
donor screening tests for prions.’’
Oocyte and sperm donors who provide
these materials (usually anonymously)
to infertile couples needing donated
gametes for IVF must meet tissue donor
eligibility requirements. FDA grants an
exception to donor eligibility requirements
for sexually intimate couples who utilize
their own oocytes and sperm for IVF;
these ‘‘tissue donors’’ only undergo a
few of the screening tests. According to
the American Society for Reproductive
Medicine, prior to IVF treatments, the
female partner’s blood type is verified,
and she is screened for conditions that
could affect the health of a pregnancy,
including immunity to rubella (German
measles) and varicella (chicken pox).
She and her male partner are both tested
for hepatitis B and C, HIV, and syphilis.
A recent study byWilkerson et al. (2013)
that explored the provenance of 198
hESC lines on the NIH Stem Cell Registry
found that 104 of the lines arose from em-
bryos donated by the biological parents.
At least eight other lines were derived
from embryos in which donor gametes
were used. For another 67 lines it was
unclear whether donated gametes were
used. Thus, because so many hESC lines
on the Registry are either of unknown
provenance or from sexually intimate
partners, the majority of hESC lines on
the NIH Stem Cell Registry did not origi-
nate from embryo donors who were
screened in accordance with FDA’s
Tissue Donor Guidance.
For basic hESC research, it does not
matter that NIH Registry hESC lines may
come from unscreened embryo donors.
However, for therapeutics development,
it matters a great deal. Problematically,
the vast majority of translational researchCell Stem Cell 14projects now being conducted in federally
funded institutions utilize NIH Registry
hESC lines; again, these are the only lines
for which they can get federal funding.
The absence of embryo donor testing in-
formation for these lines means that they
would not meet the FDA’s requirements
for a therapeutic product unless the FDA
made an exception to their guidance.
However, it is entirely unclear whether
the FDA would make such an exception,
as revealed at a joint NIH/FDA public
meeting in March 2011, ‘‘Pluripotent
Stem Cells in Translation: Early Deci-
sions.’’ The issue remains unresolved.
As has been observed, the FDA has
allowed clinical trials of NIH Registry lines;
for example, the Geron trial utilized the
line commonly known as H1, a line arising
from inadequately screened embryo
donors. It is important to note that the
FDA allows the use of an investigational
product in a clinical trial under an Inves-
tigational New Drug application (IND). An
IND does not imply FDA endorsement of
the product nor does it indicate probable
approval. It remains to be seen whether
the FDA would approve an H1-derived
product for marketing, despite the lack
of requisite donor testing prior to donation
of the embryo. According to the Tissue
Donor Guidance, any product from an
incompletely tested donor would have
to be labeled, ‘‘NOT EVALUATED FOR
INFECTIOUS SUBSTANCES.’’
The reality of therapeutics development
is that to be able to cover the high costs of
development, any university or nonprofit
research institution that has a candidate
hESC-derived product would have to
partner with industry to move past phase
1 clinical trials. But without definitive
proof of donor eligibility, private com-
panies and investors may be unlikely to
agree to get involved in commercialization
of a currently FDA-ineligible line. Given
the enormous commitment in resources
for product development, it is essential
for developers to know early on whether
moving a particular cell line forward will
be worth the investment., February 6, 2014 ª2014 Elsevier Inc. 139
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bility problem would be to screen IVF
patients for all of the infectious agents
listed in the Tissue Donor Guidance at
the time that they initiate IVF treatments.
However, the testing is expensive, and
it is not clear who would pay for the
extra tests, which for IVF patients are
neither required by regulation nor medi-
cally necessary. Although anonymous
donors of gametes will have been fully
tested, anonymous donors may not have
given consent for hESC research, posing
an ethical quandary (Wilkerson et al.,
2013). Finally, requiring additional testing
presupposes that the IVF patients would
eventually want to donate their excess
frozen embryos to research. According
to a multi-institutional survey conducted
by Lyerly et al. (2010), of IVF patients sur-
veyed who had cryopreserved embryos,
only 21% said they would be likely to
donate their embryos for research.
As an alternative, couples with excess
frozen embryos could be screened at
the time that they are considering embryo
donation. Again, it is not clear who would
pay for this testing. More importantly,
testing and interviewing at the time
of embryo donation would impose an
invasion of privacy, particularly if con-
ducted by the hESC researchers, who
are not known to the patients and who
are not necessarily clinicians. For many
IVF patients, deciding what to do with left-
over embryos is a difficult, and sometimes
agonizing experience (Lyerly et al., 2010).
Eventually, the costs of storage, prompt-
ing from the fertility clinic, and/or a desire
to bring a chapter of their life to closure
lead a couple to make a decision about
the fate of their embryos. In my experi-
ence, IVF couples want to get this over
with as simply and as quickly as possible.
To require the couples to undergo testing
and interviews in order to donate their
leftover embryos to research introduces
a substantial hurdle for these parents,
many of whom are already overwhelmed
by work and having young children at
home. Having to schedule an informed
consent discussion to donate the em-140 Cell Stem Cell 14, February 6, 2014 ª201bryos is in itself difficult. In terms of the
results of the testing, appropriate coun-
seling and treatment would need to be
made available should one or both of the
parents be found positive for an infectious
disease. Finally, a positive test for Chla-
mydia trachomatis or Neisseria gonorrhea
at the time of embryo donation would not
provide information about the status of
the donors at the time that the embryos
were created. Further increasing the
impracticability of testing is the reality
that, for a variety of reasons, including
variation in cryopreservation techniques
and age of embryos, most of the embryos
that are donated to research do not result
in an hESC line. This would render the
time, trouble, and expense of testing
embryo donors all for naught.
Testing of the hESC lines themselves
may be the only feasible option to demon-
strate infectious disease status of the
hESC lines, including those on the NIH
Registry, an option that the FDA Tissue
Donor Guidance currently does not
recognize. Assays for most of the infec-
tious diseases/agents of concern exist
and can be performed in a laboratory
setting, although some would argue that
the tests are not sensitive enough.
Indeed, in the process of making a cellular
product for human use, including use in a
clinical trial, FDA regulations require
repeated testing for HIV 1 and 2, HTLV 1
and 2, cytomegalovirus (CMV), Epstein-
Barre virus (EBV), B19, hepatitis C and B
viruses, and other adventitious agents at
multiple stages of the manufacturing
process. The only infectious agents for
which there are no FDA-approved labo-
ratory test are prions. Recent efforts at
developing, improving, and validating
prion testing (Orru` et al., 2012) could
make an enormous impact in the field of
clinical translation of hESC-derived thera-
pies, were this test to be found accept-
able in lieu of donor interviews.
In summary, NIH requirements that
funding-eligible hESC research originate
with embryos that were leftover from
fertility clinics has essentially turned
fertility patients into unwitting research4 Elsevier Inc.participants whose eligibility as tissue
donors, as per the FDA Tissue Donor
Guidance, is undetermined. The unin-
tended consequence is that the vast
majority of the hESC lines made to date,
and listed on the NIH Stem Cell Registry,
would not meet the FDA’s requirements
for commercializable starting material
for medical products. Investigators in
academia and industry alike are looking
for guidance from regulatory authorities
as to how to move past this dilemma
and develop hESC technologies into
marketable products for the treatment of
patients with serious diseases.WEB RESOURCES
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